Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Thomas, Langbein"'
Autor:
Sonia Grigorascu, Thomas Langbein, Isabel Rauscher, Calogero D’Alessandria, Tobias Maurer, Türkay Hekimsoy, Wolfgang A Weber, Matthias Eiber
Publikováno v:
EJNMMI Research, Vol 14, Iss 1, Pp 1-6 (2024)
Externí odkaz:
https://doaj.org/article/30c2ed484c634ed58ca5a9acb1035fa3
Autor:
Hui Wang, Thomas Amiel, Christoph Würnschimmel, Thomas Langbein, Katja Steiger, Isabel Rauscher, Thomas Horn, Tobias Maurer, Wolfgang Weber, Hans-Juergen Wester, Karina Knorr, Matthias Eiber
Publikováno v:
EJNMMI Research, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract Background The prostate-specific membrane antigen (PSMA) is a relevant target in prostate cancer, and immunohistochemistry studies showed associations with outcome. PSMA-ligand positron emission tomography (PET) is increasingly used for prim
Externí odkaz:
https://doaj.org/article/6873ede5c122459d8faaa935cb34206f
Autor:
Thomas Langbein, Harshad R. Kulkarni, Christiane Schuchardt, Dirk Mueller, Gerd Fabian Volk, Richard P. Baum
Publikováno v:
Diagnostics, Vol 12, Iss 8, p 1926 (2022)
Purpose: PSMA-targeted radioligand therapy (PRLT) is a promising treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). However, a high uptake of the radiopharmaceutical in the salivary glands (SG) can lead to xer
Externí odkaz:
https://doaj.org/article/b7604289a7394eff80e2be0d2b0d9cf9
Publikováno v:
Toxins, Vol 14, Iss 1, p 64 (2022)
Botulinum Toxin injections into salivary glands (SG) up to a total dose of 100 units IncobotulinumtoxinA (IncoA) represent the treatment of choice for sialorrhea. However, BTX might also protect SG against sialotoxic radioligand cancer therapies. The
Externí odkaz:
https://doaj.org/article/e48e81fc85044017a938c58448e7bfac
Autor:
Thomas Langbein, Hui Wang, Isabel Rauscher, Markus Kroenke, Karina Knorr, Alexander Wurzer, Kristina Schwamborn, Tobias Maurer, Thomas Horn, Bernhard Haller, Hans-Jürgen Wester, Matthias Eiber
Publikováno v:
Journal of Nuclear Medicine. 63:1334-1342
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1938cacb8bb901e8ca38933648ea59f4
https://doi.org/10.2967/jnumed.121.263440
https://doi.org/10.2967/jnumed.121.263440
Autor:
Lukas, Lunger, Maythinee, Chantadisai, Amir, Karimzadeh, Isabel, Rauscher, Calogero, D'Alessandria, Benedikt, Feuerecker, Thomas, Langbein, Robert, Tauber, Stefan, Schiele, Wolfgang Andreas, Weber, Matthias, Eiber
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
To assess the prognostic utility of conventional biochemical and imaging response criteria and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9715bd3cc5cd66532dc1bf69229eacb8
https://pubmed.ncbi.nlm.nih.gov/36581373
https://pubmed.ncbi.nlm.nih.gov/36581373
Publikováno v:
Der Radiologe. 61:818-824
Das Prostatakarzinom ist die haufigste maligne Erkrankung und die zweithaufigste karzinombedingte Todesursache bei Mannern in Deutschland. Eine sichere Diagnose und ein Staging mit praziser Bildgebung sind entscheidend, um den Patienten eine zielgena
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::57bac851c11758cc2d934fbc27817f32
https://doi.org/10.1007/s00117-021-00895-3
https://doi.org/10.1007/s00117-021-00895-3
Autor:
Matthias Eiber, Thomas Langbein
Publikováno v:
Radiopraxis. 14:E25-E38
In den letzten Jahren hat die PSMA-Liganden-PET vielversprechende Ergebnisse gezeigt und so enorm an Bedeutung bei der Versorgung von Prostatakarzinompatienten gewonnen. Dieser Beitrag soll einen Überblick zur PSMA-PET/CT in unterschiedlichen klinis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad9eace889ce5efbc517d0628f2500f9
https://doi.org/10.1055/a-1394-9050
https://doi.org/10.1055/a-1394-9050
Publikováno v:
Toxins
Toxins; Volume 14; Issue 1; Pages: 64
Toxins, Vol 14, Iss 64, p 64 (2022)
Toxins; Volume 14; Issue 1; Pages: 64
Toxins, Vol 14, Iss 64, p 64 (2022)
Botulinum Toxin injections into salivary glands (SG) up to a total dose of 100 units IncobotulinumtoxinA (IncoA) represent the treatment of choice for sialorrhea. However, BTX might also protect SG against sialotoxic radioligand cancer therapies. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::198769b65c96c7e6ad68b859d40b3946
https://pubmed.ncbi.nlm.nih.gov/35051042
https://pubmed.ncbi.nlm.nih.gov/35051042
Autor:
Thomas, Langbein, Hui, Wang, Isabel, Rauscher, Markus, Kroenke, Karina, Knorr, Alexander, Wurzer, Kristina, Schwamborn, Tobias, Maurer, Thomas, Horn, Bernhard, Haller, Hans-Jürgen, Wester, Matthias, Eiber
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 63(9)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4368dfadf0843c02cfce9a62e4c6702e
https://pubmed.ncbi.nlm.nih.gov/34992154
https://pubmed.ncbi.nlm.nih.gov/34992154